This hypothesis should prompt experimental studies that analyze the mechanisms of AKT activation in melanoma brain metastases and clinical studies that investigate combinations of PI3K/AKT inhibitors with BRAF/MEK inhibitors or other anticancer agents for treatment of melanoma brain metastases. Here, BRAF is linked to melanoma.